In stage T1N1M0 women participating in screening who underwent MTX had a HR of 2.91 (95% CI 1.30–6.48) for breast cancer death compared to women who underwent BCT, after adjusting for screening detection, years of diagnosis, age at diagnosis, histology, grade, and hormone receptor status. The gene discussed is NR4A1; the disease is breast carcinoma.